

Decision number: CCH-D-0000003787-61-03/F

Helsinki, 13 December 2013

DECISION ON A COMPLIANCE CHECK OF A REGISTRATION PURSUANT TO ARTICLE 41(3) OF REGULATION (EC) NO 1907/2006**For hydrocarbons, c7-c9, n-alkanes, isoalkanes, cyclics, CAS No NS (EC No 920-750-0), registration number: [REDACTED]****Addressee:** [REDACTED]

The European Chemicals Agency (ECHA) has taken the following decision in accordance with the procedure set out in Articles 50 and 51 of Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH Regulation).

I. Procedure

Pursuant to Article 41(1) of the REACH Regulation ECHA has performed a compliance check of the registration for hydrocarbons, c7-c9, n-alkanes, isoalkanes, cyclics, CAS No NS (EC No 920-750-0), submitted by [REDACTED] (Registrant). The scope of this compliance check is limited to the standard information requirement of Annex VIII, Section 8.4.3. of the REACH Regulation. ECHA stresses that it has not checked the information provided by the Registrant and other joint registrants for compliance with requirements regarding the identification of the substance (Section 2 of Annex VI).

This decision is based on the registration as submitted with submission number [REDACTED], for the tonnage band of 1000 tonnes or more per year. This decision does not take into account any updates submitted after 1 August 2013, the date upon which ECHA notified its draft decision to the Competent Authorities of the Member States pursuant to Article 51(1) of the REACH Regulation.

This compliance check decision does not prevent ECHA from initiating further compliance checks on the present registration at a later stage.

The compliance check was initiated on 15 May 2013.

On 12 June 2013 ECHA sent the draft decision to the Registrant and invited him to provide comments within 30 days of the receipt of the draft decision.

On 11 July 2013 ECHA received comments from the Registrant agreeing to ECHA's draft decision.

On 1 August 2013 ECHA notified the Competent Authorities of the Member States of its draft decision and invited them pursuant to Article 51(1) of the REACH Regulation to submit proposals to amend the draft decision within 30 days of the receipt of the notification.

Subsequently, Competent Authorities of the Member States did not propose amendments to the draft decision and ECHA took the decision pursuant to Article 51(3) of the REACH Regulation.

II. Information required

Pursuant to Articles 41(1)(a), 41(3), 10(a)(vii), 12(1)(e), 13 and Annex VIII of the REACH Regulation the Registrant shall submit the following information using the indicated test method and the registered substance subject to the present decision:

- *In vitro* gene mutation study in mammalian cells (Annex VIII, 8.4.3.; test method: EU B.17/OECD 476).

Pursuant to Article 41(4) of the REACH Regulation the Registrant shall submit the information in the form of an updated registration to ECHA by **13 December 2014**.

III. Statement of reasons

Pursuant to Article 41(3) of the REACH Regulation, ECHA may require the Registrant to submit any information needed to bring the registration into compliance with the relevant information requirements. The scope of the present decision is the *in vitro* gene mutation study in mammalian cells (Annex VIII, 8.4.3. of the REACH Regulation).

Mutagenicity, *in vitro* gene mutation study in mammalian cells.

In accordance with Articles 10(a)(vii), 12(1)(e) and with Annex VIII, section 8.4.3. of the REACH Regulation, the *in vitro* gene mutation study in mammalian cells is required if there is a negative result in the *in vitro* studies specified under Annex VII, section 8.4.1. and Annex VIII, section 8.4.2. The registration dossier reports negative results for both *in vitro* studies. Therefore the REACH Regulation requires that information on *in vitro* gene mutation in mammalian cells (Annex VIII, 8.4.3.) is provided in the dossier. ECHA notes furthermore that a cytogenicity study (be it *in vitro* or *in vivo*) cannot be used for *in vitro* or *in vivo* mammalian cell gene mutation information requirements. Cytogenicity studies and gene mutation studies are corresponding to two different endpoints and two distinct mechanisms of genotoxicity: cytogenicity studies detect structural and numerical chromosome aberrations whereas gene mutation studies detect gene or point mutations. ECHA concludes that the Registrant has neither provided this standard information nor adapted the requirement. Consequently there is an information gap and it is necessary to provide information for this endpoint.

Therefore, pursuant to Article 41(1)(a) and (3) of the REACH Regulation, the Registrant is requested to submit the following information derived with the registered substance subject to the present decision: *In vitro* mammalian cell gene mutation test (test method: EU B.17./OECD 476).

IV. Adequate identification of the composition of the tested material

ECHA stresses that the information submitted by the Registrant and other joint registrants for identifying the substance has not been checked for compliance with the substance identity requirements set out in Section 2 of Annex VI of the REACH Regulation. The Registrant is reminded of his responsibility and that of joint Registrants to ensure that the joint registration covers one substance only and that the substance is correctly identified in accordance with Annex VI, Section 2 of the REACH Regulation.

In relation to the information required by the present decision, the sample of substance used for the new study must be suitable for use by all the joint registrants. Hence, the sample should have a composition that is within the specifications of the substance composition that are given by the joint registrants. It is the responsibility of all joint registrants who manufacture or import the same substance to agree on the appropriate composition of the test material and to document the necessary information on their substance composition.

In addition, it is important to ensure that the particular sample of substance tested in the new study is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured by each registrant. If the registration of the substance by any registrant covers different grades, the sample used for the new study must be suitable to assess these grades.

Finally there must be adequate information on substance identity for the sample tested and the grade(s) registered to enable the relevance of the study to be assessed.

V. Information on right to appeal

An appeal may be brought against this decision to the Board of Appeal of ECHA under Article 51(8) of the REACH Regulation. Such an appeal shall be lodged within three months of receiving notification of this decision. Further information on the appeal procedure can be found on ECHA's internet page at http://echa.europa.eu/appeals/app_procedure_en.asp. The notice of appeal will be deemed to be filed only when the appeal fee has been paid.



Leena Ylä-Mononen
Director of Evaluation